Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03609632
Other study ID # HYPOBAR1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 20, 2018
Est. completion date November 2, 2018

Study information

Verified date December 2018
Source University Hospital Inselspital, Berne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Postprandial hyperinsulinaemic hypoglycaemia is an increasingly recognized adverse side effect of bariatric surgery. Affected individuals experience low glucose levels 1-3 hours after intake of meals, accompanied by symptoms such as drowsiness, sweating, hunger and palpitations. Hypoglycaemia can be serious and have potential dangerous health impact (e.g. road accident or fall due to loss of consciousness). The pathophysiology is incompletely understood and more research is needed in search of preventive and therapeutic strategies.


Description:

Obesity is a major global health concern that is associated with significant disability and mortality. Worldwide, the prevalence of obesity has doubled since 1980, affecting 13% of the global population. Bariatric surgery has been shown to be the most effective and durable treatment of severe obesity and leads to significant improvement of obesity-related comorbidity. However, postprandial hyperinsulinaemic hypoglycaemia (PHH) after bariatric surgery is a metabolic complication that is increasingly being recognized. Prevalence rates of up to 72% have been reported. PHH may have serious implications for affected patients, including negative effects on morbidity, mortality as well as quality of life. The pathophysiology of PPH is incompletely understood and suggests decreased adaptation of beta cell function to increased insulin sensitivity. The latter has been postulated to be largely secondary due to external factors outside the beta cells as a result of anatomical and hormonal changes after Roux-en-Y gastric bypass (RYGB). However, the intrinsic mechanistic effects of altered beta-cell function after RYGB in vivo are unknown and more exploration could lead to a better understanding of PHH pathogenesis and help identify targets for possible interventions. Previous studies performed enhanced beta cell analysis by following insulin synthesis in real-time based on stable isotope labelling of C-peptide during an oral glucose tolerance test (OGTT) in cohorts with normal and diabetic glucose tolerance. Applying the same methodological approach, albeit in a different target population (PPH after bariatric surgery), the present study seeks to explore whether or not the insulin hypersecretion can be explained by an increase in insulin synthesis, and secondly, whether potentially increased insulin synthesis can be related to other glucoregulatory hormones and measures of insulin sensitivity.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date November 2, 2018
Est. primary completion date November 2, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Gastric bypass (RYGB) surgery performed = 6 months ago

- Confirmed postprandial hypoglycaemia (continuous glucose monitoring or plasma glucose), with at least 2 episodes of Whipple's triad (symptoms, capillary of interstitial glucose =3.1mmol/L, symptom resolution by carbohydrate intake) =3 months ago

- Normal glucose control at recruitment and absence of (pre)diabetes before bariatric surgery

- Capacity to give informed consent

Exclusion Criteria:

- Fasting hypoglycaemia suggesting hyperinsulinism of different aetiology

- Use of medication that influence glucose metabolism

- Bariatric procedures other than RYGB

- Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator

- Moderate to severe chronic kidney disease

- Pregnancy or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Dietary Supplement: Glucose
Intake of 75g of glucose with 1g of 13C leucine pre-feeding

Locations

Country Name City State
Switzerland Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital Bern

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne Erasmus Medical Center

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fractional synthesis rate of de novo C-peptide synthesis (%/hr) Calculated 4.5 hours
Secondary C-peptide levels in blood Measured 4.5 hours
Secondary Insulin levels in blood Measured 4.5 hours
Secondary Glucagon levels in blood Measured 4.5 hours
Secondary Incretin levels in blood Measured 4.5 hours
Secondary Insulin sensitivity Calculated 4.5 hours
Secondary Beta cell responsivity Calculated 4.5 hours
Secondary Hepatic insulin extraction Calculated 4.5 hours
Secondary C-peptide levels in urine Measured 4.5 hours
Secondary C-peptide enrichment calculated 4.5 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04517591 - Reducing Sedentary Time in Bariatric: The Take a STAND for Health Study N/A
Active, not recruiting NCT04433338 - The PREBA Study: Effect of Preoperative Weight Loss With a 14-day Low-calorie Diet on Surgical Procedure and Outcomes in Patients Undergoing RYGB Surgery N/A
Completed NCT05854875 - Diabetes Remission After RYGBP and RYGBP With Fundus Resection N/A
Recruiting NCT06460233 - Blood Pressure Changes After Bariatric Surgery
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin
Withdrawn NCT04771247 - Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy N/A
Not yet recruiting NCT03203161 - Registry on Obesity Surgery in Adolescents
Enrolling by invitation NCT02552433 - Complications in Body Contouring Surgery
Completed NCT02525016 - Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery Phase 3
Recruiting NCT01984762 - Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus. N/A
Not yet recruiting NCT01652105 - Randomized Trial of Preoperative Diets Before Bariatric Surgery N/A
Completed NCT00989157 - Effects of Gastric Bypass on Blood Levels of Duloxetine Phase 3
Completed NCT05454696 - Online Clinic Pilates Exercises in Patients Undergoing Bariatric Surgery N/A
Completed NCT04040647 - Tolerance of Early Postoperative Mobilization and Ambulation
Recruiting NCT04297306 - Virtual Reality Exercise Gaming in Patients Awaiting Bariatric Surgery N/A
Recruiting NCT05428618 - Mobile Application for Bariatric Surgery Patients N/A
Not yet recruiting NCT03975244 - Semi-supervised Exercise Program Before Bariatric Surgery N/A
Not yet recruiting NCT03900481 - Use of an Endoluminal-suturing Device for Endoscopic Gastric Reduction as an Aid for Class I Obesity, or Class II Obesity Without Comorbidity N/A
Recruiting NCT06157606 - Prediction Model for Inadequate Weight Loss After Sleeve Gastrectomy
Recruiting NCT06218953 - The Impact of Preoperative Anemia on Postoperative Anemia and Related Nutrient Abnormalities After Bariatric Surgery